+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)

PRINTER FRIENDLY

Global Human Microbiome Sequencing Market: Focus on Products, Technologies, Applications, End Users, Country Data (17 Countries), and Competitive Landscape - Analysis and Forecast, 2018-2029

  • ID: 5019047
  • Report
  • March 2020
  • Region: Global
  • 222 Pages
  • BIS Research
1 of 5

Enquire about COVID-19 updates for this product.

Enquire Now
Global Human Microbiome Sequencing Market to Reach $6,336.4 Million by 2029

FEATURED COMPANIES

  • Baseclear B.V.
  • CosmosID
  • GENEWIZ, Inc.
  • Microba
  • Molzym GmbH & Co. KG
  • QIAGEN N.V.
  • MORE

Key Questions Answered in this Report:

  • What are the long-term and short-term impacts of human microbiome sequencing on the human health continuum?
  • What are the major market drivers, challenges, and opportunities in the global human microbiome sequencing market?
  • What are the key development strategies which are implemented by the major players in order to sustain in the competitive market?
  • What are the key regulatory implications in developed and developing regions for the global human microbiome sequencing market?
  • How is the patent landscape in the industry shaping up future technological trends?
  • How is each segment of the market expected to grow during the forecast period from 2019 to 2029?
  • Who are the leading players with significant offerings to the global human microbiome sequencing market? What is the expected market dominance for each of these leading players?
  • Which companies are anticipated to be highly disruptive in the future, and why?
  • What are the challenges that are yet to be met by the global human microbiome sequencing market?
  • What are the unmet needs of the human microbiome sequencing market?

Key USPs of the Report

Following are some of the key sections of the report

Industry Analysis (Section 4)

The industry analysis section encompasses analyses such as patent analysis, regulatory landscape, and awaited technological developments. The patent analysis section covers the filing trend and analyzes its growing impact on the market. This section will aid the readers in staying updated with the latest regulations as well as discuss how the market is likely to unfold during the next ten years.

Competitive Landscape (section 5)

The section comprises the following information:

  • Market Share Analysis

The section includes key insights on the revenue share of the players operating in the market, both for manufacturers and service providers. It will provide information on who the leading players in the market are. The section will also include growth-share analysis of the key players and key applications in the study.

  • Key Strategies and Developments

The section provides information on the recent developments in the market, which includes the following categories - funding activities, M&A activities, partnerships, alliances & business expansions, regulatory & legal, new offerings, and procurement & sales.

Global Market Scenario (section 6)

The section encompasses the detailed description and impacts analysis for the market dynamics, i.e., growth factors, challenges, and market opportunities.

In addition, the report provides a detailed analysis and growth forecast for each segment in the subsequent sections. Country-wise analysis has been provided for 17 leading countries across the globe.

Expert Quote

Market Potential

“I believe that the market size for human microbiome sequencing will be in excess of $6.00 Billion by 2029 and will grow rapidly due to the large number of initiatives that are being undertaken globally. In addition, the decreasing cost of sequencing and the emergence of star-ups in the direct-to-consumer market will increasingly bolster the overall market scenario.”

End-to-End Service Providers

“The industry has been largely driven by the very high number of companies entering the market through their direct-to-consumer business model. Companies such as Viome, Inc. are uniquely poised to disrupt the market with the kind of funding they have been receiving. In addition, consumer wellness is anticipated to become a centerpiece for this massively growing market, especially with a growing focus on the skin microbiome.”

Scope of the Global Human Microbiome Sequencing Market

The report constitutes an in-depth study of the global human microbiome sequencing market. The study also presents a detailed analysis of the market dynamics and estimation of the market size over the forecast period, 2019-2029. The scope of this report is focused on the analysis of the human microbiome sequencing market by product type, by technology, by application, by end user, and their country-wise analysis.

Key Companies in the Global Human Microbiome Sequencing Market

Some of the key players contributing to the global human microbiome sequencing market are Baseclear B.V., Beijing Genomics Institute (BGI) Genomics Co., Ltd, Charles River Laboratories International Inc., Clinical Microbiomics A/S, Eurofins Scientific SE, GENEWIZ, Inc., Illumina, Inc., Novogene Corporation, OraSure Technologies, Inc., Oxford Nanopore Technologies, Inc., Pacific Biosciences of California, Inc., QIAGEN N.V., Second Genome, Inc., Thermo Fisher Scientific Inc., Viome, Inc., CosmosID, Leucine Rich Bio Pvt. Ltd., Microba, Microbiome Insights Inc., and Molzym GmbH & Co. KG.

Enterprise License customers will receive an Excel spreadsheet containing additional data.

Note: Product cover images may vary from those shown
2 of 5

FEATURED COMPANIES

  • Baseclear B.V.
  • CosmosID
  • GENEWIZ, Inc.
  • Microba
  • Molzym GmbH & Co. KG
  • QIAGEN N.V.
  • MORE

Executive Summary

1 Product-Service Definition
1.1 Inclusion and Exclusion

2 Research Scope
2.1 Scope of the Study
2.2 Key Questions Answered in the Report
2.3 Global Human Microbiome Sequencing Market: Research Methodology

3 Research Methodology
3.1 Primary Data Sources
3.2 Secondary Data Sources
3.3 Market Estimation Model

4 Industry Analysis
4.1 Overview
4.2 Legal Requirements and Framework in the U.S.
4.3 Legal Requirements and Framework in Europe
4.4 Legal Requirements and Framework in Asia-Pacific
4.4.1 China
4.4.2 Japan
4.5 Patent Analysis

5 Competitive Landscape
5.1 Synergistic Activities
5.2 Product Launches and Upgrades
5.3 Business Expansion and Funding Activities
5.4 Mergers and Acquisitions
5.5 Product Approvals and Other Activities
5.6 Market Share Analysis, 2017-2018
5.7 Growth Share Analysis
5.7.1 Growth Share Analysis (by Company)
5.7.2 Growth Share Analysis (by Application)

6 Market Dynamics
6.1 Overview
6.2 Iceberg Analysis - Global Human Microbiome Sequencing Market
6.3 Impact Analysis
6.4 Market Drivers
6.4.1 Increasing Emphasis on Microbiome’s Potential for Human Health
6.4.2 Decreasing Cost of Sequencing
6.4.3 Increasing Entry of Legacy Companies into Microbiome Sequencing
6.5 Market Restraints
6.5.1 Lack of High Complexity Testing Centers
6.5.2 Insufficient Application-Based Research Hindering Market Pull
6.5.3 Regulatory Challenges for Direct-to-Consumer (DTC) Companies
6.6 Market Opportunities
6.6.1 Massive Scope for Adoption of Human Microbiome Sequencing in Developing Nations
6.6.2 Growing Integrative Industry-Academia Collaboration
6.6.3 Novel Diagnostic Applications

7 Human Microbiome Sequencing: Overview
7.1 Introduction
7.2 Milestones in Human Microbiota Research
7.3 Market Availability for Human Microbiome Sequencing

8 Global Human Microbiome Sequencing Market (by Product Type)
8.1 Overview
8.2 Kits and Assays
8.3 Instruments
8.4 Software

9 Global Human Microbiome Sequencing Market (by Technology)
9.1 Overview
9.2 Next-Generation Sequencing
9.2.1 Sequencing by Synthesis
9.2.2 Sequencing by Ligation
9.2.3 Other Next-Generation Sequencing Technologies
9.3 Traditional Sequencing Technologies
9.3.1 Pyrosequencing
9.3.2 Sanger Sequencing
9.4 Other Sequencing Technologies

10 Global Human Microbiome Sequencing Market (by Application)
10.1 Overview
10.2 Disease Diagnosis
10.2.1 Gastrointestinal Diseases
10.2.2 Metabolic Diseases
10.2.3 Oncology
10.2.4 Infectious Diseases
10.2.5 Neurological Diseases
10.2.6 Other Diseases
10.3 Drug Discovery
10.4 Consumer Wellness
10.5 Omics Analysis
10.5.1 Genome Analysis
10.5.2 Metabolome Analysis
10.5.3 Transcriptome Analysis
10.5.4 Other Omics Analysis
10.6 Other Applications

11 Global Human Microbiome Sequencing (by End User)
11.1 Overview
11.2 Research and Academic Institutions
11.3 Pharmaceutical and Biotechnology Companies
11.4 Other End Users

12 Global Human Microbiome Sequencing Market (by Region)
12.1 Overview
12.2 North America
12.2.1 U.S.
12.2.2 Canada
12.3 Europe
12.3.1 Germany
12.3.2 France
12.3.3 U.K.
12.3.4 Spain
12.3.5 Italy
12.3.6 Russia
12.3.7 Rest-of-Europe
12.4 Asia-Pacific
12.4.1 China
12.4.2 Japan
12.4.3 India
12.4.4 Australia
12.4.5 South Korea
12.4.6 Singapore
12.4.7 Rest-of-APAC
12.5 Latin America
12.5.1 Brazil
12.5.2 Mexico
12.5.3 Argentina
12.5.4 Rest-of-Latin America
12.6 Rest-of-the-World

13 Company Profiles
13.1 Overview
13.2 Market Value Chain
13.3 Baseclear B.V.
13.3.1 Company Overview
13.3.2 Role of Baseclear B.V. in the Global Human Microbiome Sequencing Market
13.3.3 SWOT Analysis
13.4 Beijing Genomics Institute (BGI) Genomics Co., Ltd
13.4.1 Company Overview
13.4.2 Role of Beijing Genomics Institute (BGI) Genomics Co., Ltd in the Global RNA Sequencing Market
13.4.3 Financials
13.4.4 Key Insights About Financial Health of the Company
13.4.5 SWOT Analysis
13.5 Charles River Laboratories International Inc.
13.5.1 Company Overview
13.5.2 Role of Charles River Laboratories International Inc. in the Global Human Microbiome Sequencing Market
13.5.3 Financials
13.5.4 SWOT Analysis
13.6 Clinical Microbiomics A/S
13.6.1 Company Overview
13.6.2 Role of Clinical Microbiomics A/S in the Global Human Microbiome Sequencing Market
13.6.3 SWOT Analysis
13.7 Eurofins Scientific SE
13.7.1 Company Overview
13.7.2 Role of Eurofins Scientific SE in the Global Human Microbiome Sequencing Market
13.7.3 Financials
13.7.4 SWOT Analysis
13.8 GENEWIZ, Inc.
13.8.1 Company Overview
13.8.2 Role of GENEWIZ, Inc. in the Global Human Microbiome Sequencing Market
13.8.3 SWOT Analysis
13.9 Illumina, Inc.
13.9.1 Company Overview
13.9.2 Role of Illumina, Inc. in the Global Human Microbiome Sequencing Market
13.9.3 Financials
13.9.4 Key Insights About Financial Health of the Company
13.9.5 SWOT Analysis
13.10 Novogene Corporation
13.10.1 Company Overview
13.10.2 Role of Novogene Corporation in the Global Human Microbiome Sequencing Market
13.10.3 SWOT Analysis
13.11 OraSure Technologies, Inc.
13.11.1 Company Overview
13.11.2 Role of OraSure Technologies, Inc. in the Global Human Microbiome Sequencing Market
13.11.3 Financials
13.11.4 Key Insights About Financial Health of the Company
13.11.5 SWOT Analysis
13.12 Oxford Nanopore Technologies, Inc.
13.12.1 Company Overview
13.12.2 Role of Oxford Nanopore Technologies, Inc. in the Global Human Microbiome Sequencing Market
13.12.3 SWOT Analysis
13.13 Pacific Biosciences of California, Inc.
13.13.1 Company Overview
13.13.2 Role of Pacific Biosciences of California, Inc. in the Global Human Microbiome Sequencing Market
13.13.3 Financials
13.13.4 Key Insights About Financial Health of the Company
13.13.5 SWOT Analysis
13.14 QIAGEN N.V.
13.14.1 Company Overview
13.14.2 Role of QIAGEN N.V. plc in the Global Human Microbiome Sequencing Market
13.14.3 Financials
13.14.4 Key Insights About Financial Health of the Company
13.14.5 SWOT Analysis
13.15 Second Genome, Inc.
13.15.1 Company Overview
13.15.2 Role of Second Genome, Inc. in the Global Human Microbiome Sequencing Market
13.15.3 SWOT Analysis
13.16 Thermo Fisher Scientific Inc.
13.16.1 Company Overview
13.16.2 Role of Thermo Fisher Scientific Inc. in the Global Human Microbiome Sequencing Market
13.16.3 Financials
13.16.4 Key Insights About Financial Health of the Company
13.16.5 SWOT Analysis
13.17 Viome, Inc.
13.17.1 Company Overview
13.17.2 Role of Viome, Inc. in the Global Human Microbiome Sequencing Market
13.17.3 SWOT Analysis
13.18 CosmosID
13.18.1 Company Overview
13.18.2 Role of CosmosID in the Global Human Microbiome Sequencing Market
13.19 Leucine Rich Bio Pvt. Ltd.
13.19.1 Company Overview
13.19.2 Role of Leucine Rich Bio Pvt. Ltd. in the Global Human Microbiome Sequencing Market
13.20 Microba
13.20.1 Company Overview
13.20.2 Role of Microba in the Global Human Microbiome Sequencing Market
13.21 Microbiome Insights Inc.
13.21.1 Company Overview
13.21.2 Role of Microbiome Insights Inc. in the Global Human Microbiome Sequencing Market
13.22 Molzym GmbH & Co. KG
13.22.1 Company Overview
13.22.2 Role of Molzym GmbH & Co. KG in the Global Human Microbiome Sequencing Market

List of Tables

Table 8.1: Examples of Kits and Assays in Global Human Microbiome Sequencing Market
Table 8.2: Examples of Instruments in Global Human Microbiome Sequencing Market
Table 8.3: Examples of Software in Global Human Microbiome Sequencing Market

List of Figures

Figure 1: Annual NIH Funding in Human Microbiome Research, FY2007-FY2016
Figure 2: Impact Analysis of Market Drivers and Market Challenges on the Global Human Microbiome Sequencing Market
Figure 3: Global Human Microbiome Sequencing Market (by Product), 2018 vs. 2029 ($Million)
Figure 4: Global Human Microbiome Sequencing Market (by Technology), 2018 vs. 2029 ($Million)
Figure 5: Global Human Microbiome Sequencing Market (by Application), 2018 vs. 2029 ($Million)
Figure 6: Global Human Microbiome Sequencing Market (by End User), 2018 vs. 2029 ($Million)
Figure 7: Global Human Microbiome Sequencing Market Snapshot
Figure 2.1: Global Human Microbiome Sequencing Market Segmentation
Figure 2.2: Global Human Microbiome Sequencing Market Methodology
Figure 3.1: Bottom-Up Approach (Segment-Wise Analysis)
Figure 3.2: Top-Down Approach (Segment-Wise Analysis)
Figure 5.1: Share of Key Developments and Strategies, January 2016–February 2020
Figure 5.2: Synergistic Activities Share (by Company), January 2016–February 2020
Figure 5.3: Product Launches Share (by Company), January 2016 – February 2020
Figure 5.4: Business Expansion Activities Share (by Company), January 2016 – February 2020
Figure 5.5: Market Share Analysis for Global Human Microbiome Sequencing Market, 2017 and 2018
Figure 5.6: Growth Share Analysis for Global Human Microbiome Sequencing Market (by Company), 2018
Figure 5.7: Growth Share Analysis for Global Human Microbiome Sequencing Market (by Application), 2018-2029
Figure 6.1: Iceberg Analysis - Global Human Microbiome Sequencing Market
Figure 6.2: Impact Analysis
Figure 6.3: Annual NIH Funding in the Human Microbiome Research, FY2007-FY2016
Figure 6.4: Decreasing Cost and Increasing Output (TB) of Genome Sequencing (2009-2025)
Figure 7.1: Milestones in Human Microbiota Research
Figure 7.2: Global Human Microbiome Sequencing Market, 2018-2029
Figure 8.1: Global Human Microbiome Sequencing Market (by Product Type)
Figure 8.2: Global Human Microbiome Sequencing Market (by Product Type), 2018 and 2029
Figure 8.3: Global Human Microbiome Sequencing Market (by Kits and Assays), 2018-2029
Figure 8.4: Global Human Microbiome Sequencing Market (by Instruments), 2018-2029
Figure 8.5: Global Human Microbiome Sequencing Market (by Software), 2018-2029
Figure 9.1: Global Human Microbiome Sequencing Market (by Technology)
Figure 9.2: Global Human Microbiome Sequencing Market (by Technology), 2018-2029
Figure 9.3: Global Human Microbiome Sequencing Market (by Next-Generation Sequencing), 2018 and 2029
Figure 9.4: Global Human Microbiome Sequencing Market (by Sequencing by Synthesis), 2018-2029
Figure 9.5: Global Human Microbiome Sequencing Market (by Sequencing by Ligation), 2018-2029
Figure 9.6: Global Human Microbiome Sequencing Market (by Other Next-Generation Sequencing Technologies), 2018-2029
Figure 9.7: Global Human Microbiome Sequencing Market (by Traditional Sequencing Technologies), 2018 and 2029
Figure 9.8: Global Human Microbiome Sequencing Market (by Pyrosequencing), 2018-2029
Figure 9.9: Global Human Microbiome Sequencing Market (by Sanger Sequencing), 2018-2029
Figure 9.10: Global Human Microbiome Sequencing Market (by Other Sequencing Technologies), 2018-2029
Figure 10.1: Global Human Microbiome Sequencing Market (by Application)
Figure 10.2: Global Human Microbiome Sequencing Market (by Application), 2018-2029
Figure 10.3: Global Human Microbiome Sequencing Market (by Disease Diagnosis), 2018 and 2029
Figure 10.4: Global Human Microbiome Sequencing Market (Gastrointestinal Disease), 2018-2029
Figure 10.5: Global Human Microbiome Sequencing Market (by Metabolic Diseases), 2018-2029
Figure 10.6: Global Human Microbiome Sequencing Market (by Oncology), 2018-2029
Figure 10.7: Global Human Microbiome Sequencing Market (Infectious Diseases), 2018-2029
Figure 10.8: Global Human Microbiome Sequencing Market (Neurological Diseases), 2018-2029
Figure 10.9: Global Human Microbiome Sequencing Market (Other Diseases), 2018-2029
Figure 10.10: Global Human Microbiome Sequencing Market (by Drug Discovery), 2018-2029
Figure 10.11: Global Human Microbiome Sequencing Market (by Drug Discovery), 2018-2029
Figure 10.12: Global Human Microbiome Sequencing Market (by Omics Analysis), 2018 and 2029
Figure 10.13: Global Human Microbiome Sequencing Market (by Genome Analysis),2018-2029
Figure 10.14: Global Human Microbiome Sequencing Market (by Metabolome Analysis), 2018-2029
Figure 10.15: Global Human Microbiome Sequencing Market (by Transcriptome Analysis), 2018-2029
Figure 10.16: Global Human Microbiome Sequencing Market (by Other Omics Analysis), 2018-2029
Figure 10.17: Global Human Microbiome Sequencing Market (by Other Applications), 2018-2029
Figure 11.1: Global Human Microbiome Sequencing Market (by End User)
Figure 11.2: Global Human Microbiome Sequencing Market (by Research and Academic Institutions), 2018-2029
Figure 11.3: Global Human Microbiome Sequencing Market (by Pharmaceutical and Biotechnology Companies), 2018-2029
Figure 11.4: Global Human Microbiome Sequencing Market (by Other End Users), 2018-2029
Figure 12.1: Global Human Microbiome Sequencing Market (by Region)
Figure 12.2: Global Human Microbiome Sequencing Market (by Region), 2018-2029
Figure 12.3: Global Human Microbiome Sequencing Market Share (by Region), 2018 and 2029
Figure 12.4: North America Human Microbiome Sequencing Market, 2018-2029
Figure 12.5: North America: Market Dynamics
Figure 12.6: North America Human Microbiome Sequencing Market (by Country), 2018-2029
Figure 12.7: U.S. Human Microbiome Sequencing Market, 2018-2029
Figure 12.8: Canada Human Microbiome Sequencing Market, 2018-2029
Figure 12.9: Europe Human Microbiome Sequencing Market, 2018-2029
Figure 12.10: Europe: Market Dynamics
Figure 12.11: Europe Human Microbiome Sequencing Market (by Country), 2018-2029
Figure 12.12: Germany Human Microbiome Sequencing Market, 2018-2029
Figure 12.13: France Human Microbiome Sequencing Market, 2018-2029
Figure 12.14: U.K. Human Microbiome Sequencing Market, 2018-2029
Figure 12.15: Spain Human Microbiome Sequencing Market, 2018-2029
Figure 12.16: Italy Human Microbiome Sequencing Market, 2018-2029
Figure 12.17: Russia Human Microbiome Sequencing Market, 2018-2029
Figure 12.18: Rest-of-Europe Human Microbiome Sequencing Market, 2018-2029
Figure 12.19: Asia-Pacific Human Microbiome Sequencing Market, 2018-2029
Figure 12.20: APAC: Market Dynamics
Figure 12.21: APAC Human Microbiome Sequencing Market (by Country), 2018-2029
Figure 12.22: China Human Microbiome Sequencing Market, 2018-2029
Figure 12.23: Japan Human Microbiome Sequencing Market, 2018-2029
Figure 12.24: India Human Microbiome Sequencing Market, 2018-2029
Figure 12.25: Australia Human Microbiome Sequencing Market, 2018-2029
Figure 12.26: South Korea Human Microbiome Sequencing Market, 2018-2029
Figure 12.27: Singapore Human Microbiome Sequencing Market, 2018-2029
Figure 12.28: RoAPAC Human Microbiome Sequencing Market, 2018-2029
Figure 12.29: Latin America Human Microbiome Sequencing Market, 2018-2029
Figure 12.30: Latin America: Market Dynamics
Figure 12.31: Latin America Human Microbiome Sequencing Market (by Country), 2018-2029
Figure 12.32: Brazil Human Microbiome Sequencing Market, 2018-2029
Figure 12.33: Mexico Human Microbiome Sequencing Market, 2018-2029
Figure 12.34: Argentina Human Microbiome Sequencing Market, 2018-2029
Figure 12.35: Rest-of-Latin America Human Microbiome Sequencing Market, 2018-2029
Figure 12.36: RoW Human Microbiome Sequencing Market, 2018-2029
Figure 13.1: Global Human Microbiome Sequencing Market: Value Chain
Figure 13.2: Baseclear B.V.: Overall Service Portfolio
Figure 13.3: Baseclear B.V.: SWOT Analysis
Figure 13.4: Beijing Genomics Institute (BGI) Genomics Co., Ltd: Overall Service Portfolio
Figure 13.5: Beijing Genomics Institute (BGI) Genomics Co., Ltd: Overall Financials, 2017-2018
Figure 13.6: Beijing Genomics Institute (BGI) Genomics Co., Ltd: Sales (by Segment), 2017-2018
Figure 13.7: Beijing Genomics Institute (BGI) Genomics Co., Ltd: Sales (by Region), 2017-2018
Figure 13.8: Beijing Genomics Institute (BGI) Genomics Co., Ltd: R&D Expenditure, 2017-2018
Figure 13.9: Beijing Genomics Institute (BGI) Genomics Co., Ltd: SWOT Analysis
Figure 13.10: Charles River Laboratories International Inc.: Overall Service Portfolio
Figure 13.11: Charles River Laboratories International Inc.: Overall Financials, 2016-2018
Figure 13.12: Charles River Laboratories International Inc.: Revenue (by Segment), 2016-2018
Figure 13.13: Charles River Laboratories International Inc.: Revenue (by Region), 2016-2018
Figure 13.14: Charles River Laboratories International Inc.: SWOT Analysis
Figure 13.15: Clinical Microbiomics A/S: Service Offerings
Figure 13.16: Clinical Microbiomics A/S: SWOT Analysis
Figure 13.17: Eurofins Scientific SE: Service Portfolio
Figure 13.18: Eurofins Scientific SE: Overall Financials, 2016-2018
Figure 13.19: Eurofins Scientific SE: Revenue (by Region), 2016-2018
Figure 13.20: Eurofins Scientific SE.: SWOT Analysis
Figure 13.21: GENEWIZ, Inc.: Overall Service Portfolio
Figure 13.22: GENEWIZ, Inc.: SWOT Analysis
Figure 13.23: Illumina, Inc.: Overall Product Portfolio
Figure 13.24: Illumina, Inc.: Overall Financials, 2016-2018
Figure 13.25: Illumina, Inc.: Revenue (by Segment), 2016-2018
Figure 13.26: Illumina, Inc.: Revenue (by Region), 2016-2018
Figure 13.27: Illumina, Inc.: R&D Expenditure, 2016-2018
Figure 13.28: Illumina, Inc.: SWOT Analysis
Figure 13.29: Novogene Corporation: Overall Service Portfolio
Figure 13.30: Novogene Corporation: SWOT Analysis
Figure 13.31: OraSure Technologies, Inc.: Overall Service Portfolio
Figure 13.32: OraSure Technologies, Inc.: Overall Financials, 2016-2018
Figure 13.33: OraSure Technologies, Inc.: Sales (by Segment), 2016-2018
Figure 13.34: OraSure Technologies, Inc.: Sales (by Region), 2016-2018
Figure 13.35: OraSure Technologies, Inc.: R&D Expenditure, 2016-2018
Figure 13.36: OraSure Technologies, Inc.: SWOT Analysis
Figure 13.37: Oxford Nanopore Technologies, Inc.: Product Offerings
Figure 13.38: Oxford Nanopore Technologies, Inc.: SWOT Analysis
Figure 13.39: Pacific Biosciences of California, Inc.: Overall Product Portfolio
Figure 13.40: Pacific Biosciences of California, Inc.: Overall Financials, 2016-2018
Figure 13.41: Pacific Biosciences of California, Inc.: Revenue (by Segment), 2016-2018
Figure 13.42: Pacific Biosciences of California, Inc.: Revenue (by Region), 2016-2018
Figure 13.43: Pacific Biosciences of California, Inc.: R&D Expenditure, 2016-2018
Figure 13.44: Pacific Biosciences of California, Inc.: SWOT Analysis
Figure 13.45: QIAGEN N.V.: Overall Product Portfolio
Figure 13.46: QIAGEN N.V.: Overall Financials, 2016-2018
Figure 13.47: QIAGEN N.V.: Revenue (by Segment), 2016-2018
Figure 13.48: QIAGEN N.V.: Revenue (by Region), 2016-2018
Figure 13.49: QIAGEN N.V.: R&D Expenditure, 2016-2018
Figure 13.50: QIAGEN N.V.: SWOT Analysis
Figure 13.51: Second Genome, Inc.: Service Offerings
Figure 13.52: Second Genome, Inc.: SWOT Analysis
Figure 13.53: Thermo Fisher Scientific Inc.: Overall Product and Service Portfolio
Figure 13.54: Thermo Fisher Scientific Inc.: Overall Financials, 2016-2018
Figure 13.55: Thermo Fisher Scientific Inc: Sales (by Segment), 2016-2018
Figure 13.56: Thermo Fisher Scientific Inc.: Sales (by Region), 2016-2018
Figure 13.57: Thermo Fisher Scientific Inc.: R&D Expenditure, 2016-2018
Figure 13.58: Thermo Fisher Scientific Inc.: SWOT Analysis
Figure 13.59: Viome, Inc.: Product Offerings
Figure 13.60: Viome, Inc.: SWOT Analysis
Figure 13.61: CosmosID: Service Offerings
Figure 13.62: Leucine Rich Bio Pvt. Ltd.: Service Offerings
Figure 13.63: Microba: Service Offerings
Figure 13.64: Microbiome Insights Inc.: Service Offerings
Figure 13.65: Molzym GmbH & Co. KG: Product Offerings

Note: Product cover images may vary from those shown
3 of 5

Loading
LOADING...

4 of 5

FEATURED COMPANIES

  • Baseclear B.V.
  • CosmosID
  • GENEWIZ, Inc.
  • Microba
  • Molzym GmbH & Co. KG
  • QIAGEN N.V.
  • MORE

According to the market intelligence report, titled “Global Human Microbiome Sequencing Market - Analysis and Forecast: 2018-2029”, the market for human microbiome sequencing is anticipated to clock a CAGR of 19.44% during the forecast period 2019-2029. As high-throughput approaches continue to advance and become clinically corroborated, it is expected that next-generation sequencing will be at the forefront as a method for understanding host-microbiome relationships, leading to a highly flourishing human microbiome sequencing market. The market is expected to grow up to $6,336.4 million by the end of 2029.

Although at its nascency, the human microbiome has progressively become an inseparable part of human health owing to the increasing number of global initiatives establishing its symbiotic role in the upkeep of human health. While probiotic-based products have already made their entry into the market, primarily based on the historical research profiling general human gut microbiota, global initiatives are now being undertaken to emphasize the role of the human microbiome as a “second genome”. Large-scale sequencing studies, attempting to replicate the global genome sequencing initiatives, have delved deeper into understanding human microbiome variation across demographics. The central role of the gut microbiota in modulating human health has further expanded into understanding its role in modulating other metabolic factors in the human body. As a result, human microbiome sequencing has become the centerpiece of an ever-evolving precision medicine landscape. Growing interests across the healthcare continuum worldwide have rendered a highly dynamic market, dotted with mushrooming start-ups that have disrupted testing accessibility. Further, growing adoption among the global population has also facilitated enormous growth and will continue to propel the overall market.

According to Aditya Chatterjee, Analyst, “Disease diagnosis is expected to remain the leading application by the end of 2029. Disease diagnosis contributed to 41.95% of the market revenue in 2018 and is anticipated to hold a 37.10% share of the market in 2029. However, consumer wellness is expected to be the fastest-growing application, far outpacing the likes of drug discovery and omics analysis.”

Research Highlights:

Leading players in the global human microbiome sequencing market focus on undertaking synergistic activities with emerging start-ups in order to further expand their product portfolio.

The funding and business expansion scenario in the global human microbiome sequencing market has been a tremendous driving factor in bolstering the overall market. With the aim of advancing research through investments, legacy healthcare companies have invested significantly in start-ups to aid in product commercialization.

This market intelligence report provides a multidimensional view of the global human microbiome sequencing market in terms of market size and growth potential. This research report aims at answering various aspects of the human microbiome sequencing market with the help of the key factors driving the market, threats that can inhibit the overall market growth, and the current growth opportunities that are going to shape the future trajectory of market expansion.

Furthermore, the competitive landscape chapter in the report explicates the competitive nature of the global market and enables the reader to get acquainted with the recent market activities such as M&A activities, regulatory and legal activities, partnerships, and alliances and business expansion activities. The research report provides a comprehensive analysis of sales value, and manufacturers and trend analysis by segment and demand analysis by region.

This report is a meticulous compilation of research on more than 15 players in the market ecosystem and draws upon insights from in-depth interviews with the key opinion leaders of the leading companies, market participants, and vendors.

Note: Product cover images may vary from those shown
5 of 5
  • Baseclear B.V.
  • Beijing Genomics Institute (BGI) Genomics Co., Ltd
  • Charles River Laboratories International Inc.
  • Clinical Microbiomics A/S
  • CosmosID
  • Eurofins Scientific SE
  • GENEWIZ, Inc.
  • Illumina, Inc.
  • Leucine Rich Bio Pvt. Ltd.
  • Microba
  • Microbiome Insights Inc.
  • Molzym GmbH & Co. KG
  • Novogene Corporation
  • OraSure Technologies, Inc.
  • Oxford Nanopore Technologies, Inc.
  • Pacific Biosciences of California, Inc.
  • QIAGEN N.V.
  • Second Genome, Inc.
  • Thermo Fisher Scientific Inc.
  • Viome, Inc.
Note: Product cover images may vary from those shown
Adroll
adroll